TY - JOUR
T1 - A gene-alteration profile of human lung cancer cell lines
AU - Blanco, Raquel
AU - Iwakawa, Reika
AU - Tang, Moying
AU - Kohno, Takashi
AU - Angulo, Barbara
AU - Pio, Ruben
AU - Montuenga, Luis M.
AU - Minna, John D.
AU - Yokota, Jun
AU - Sanchez-Cespedes, Montse
PY - 2009/8
Y1 - 2009/8
N2 - Aberrant proteins encoded from genes altered in tumors drive cancer development and may also be therapeutic targets. Here we derived a comprehensive gene-alteration profile of lung cancer cell lines. We tested 17 genes in a panel of 88 lung cancer cell lines and found the rates of alteration to be higher than previously thought. Nearly all cells feature inactivation at TP53 and CDKN2A or RB1, whereas BRAF, MET, ERBB2, and NRAS alterations were infrequent. A preferential accumulation of alterations among histopathological types and a mutually exclusive occurrence of alterations of CDKN2A and RB1 as well as of KRAS, epidermal growth factor receptor (EGFR), NRAS, and ERBB2 were seen. Moreover, in nonsmall-cell lung cancer (NSCLC), concomitant activation of signal transduction pathways known to converge in mammalian target of rapamycin (mTOR) was common. Cells with single activation of ERBB2, PTEN, or MET signaling showed greater sensitivity to cell-growth inhibition induced by erlotinib, LY294002, and PHA665752, respectively, than did cells featuring simultaneous activation of these pathways, underlining the need for combined therapeutic strategies in targeted cancer treatments. In conclusion, our gene-alteration landscape of lung cancer cell lines provides insights into how gene alterations accumulate and biological pathways interact in cancer.
AB - Aberrant proteins encoded from genes altered in tumors drive cancer development and may also be therapeutic targets. Here we derived a comprehensive gene-alteration profile of lung cancer cell lines. We tested 17 genes in a panel of 88 lung cancer cell lines and found the rates of alteration to be higher than previously thought. Nearly all cells feature inactivation at TP53 and CDKN2A or RB1, whereas BRAF, MET, ERBB2, and NRAS alterations were infrequent. A preferential accumulation of alterations among histopathological types and a mutually exclusive occurrence of alterations of CDKN2A and RB1 as well as of KRAS, epidermal growth factor receptor (EGFR), NRAS, and ERBB2 were seen. Moreover, in nonsmall-cell lung cancer (NSCLC), concomitant activation of signal transduction pathways known to converge in mammalian target of rapamycin (mTOR) was common. Cells with single activation of ERBB2, PTEN, or MET signaling showed greater sensitivity to cell-growth inhibition induced by erlotinib, LY294002, and PHA665752, respectively, than did cells featuring simultaneous activation of these pathways, underlining the need for combined therapeutic strategies in targeted cancer treatments. In conclusion, our gene-alteration landscape of lung cancer cell lines provides insights into how gene alterations accumulate and biological pathways interact in cancer.
KW - Lung cancer
KW - Oncogenes
KW - Tumor suppressors
KW - Tyrosine kinase inhibitors
UR - http://www.scopus.com/inward/record.url?scp=67749108202&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67749108202&partnerID=8YFLogxK
U2 - 10.1002/humu.21028
DO - 10.1002/humu.21028
M3 - Article
C2 - 19472407
AN - SCOPUS:67749108202
SN - 1059-7794
VL - 30
SP - 1199
EP - 1206
JO - Human mutation
JF - Human mutation
IS - 8
ER -